Case Reports

Section edited by Alfred Zippelius, MD

Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.

Previous Page Page 2 of 3 Next Page
  1. Case report

    Acute visual loss after ipilimumab treatment for metastatic melanoma

    Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related ...

    Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter and Leslie A. Fecher

    Journal for ImmunoTherapy of Cancer 2016 4:66

    Published on: 18 October 2016

  2. Case report

    Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade

    Antibodies against programmed death 1 (PD-1) receptor and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) have transformed the systemic treatment of melanoma and many other cancers. Understanding the spec...

    Katy K. Tsai, Miguel H. Pampaloni, Charity Hope, Alain P. Algazi, Britt-Marie Ljung, Laura Pincus and Adil I. Daud

    Journal for ImmunoTherapy of Cancer 2016 4:58

    Published on: 20 September 2016

  3. Case report

    A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

    Immune related adverse events (irAEs) are common side effects of checkpoint inhibitory (CPI) therapies targeting CTLA-4 and PD-1/PD-L1. Grover’s disease is an uncommon dermatologic condition with unclear patho...

    Marc Uemura, Faisal Faˈak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff and Adi Diab

    Journal for ImmunoTherapy of Cancer 2016 4:55

    Published on: 20 September 2016

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:7

  4. Case report

    Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy

    Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (P...

    Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius and Kirsten D. Mertz

    Journal for ImmunoTherapy of Cancer 2016 4:47

    Published on: 16 August 2016

  5. Short report

    Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

    Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, a...

    Lucie Heinzerling, Patrick A. Ott, F. Stephen Hodi, Aliya N. Husain, Azadeh Tajmir-Riahi, Hussein Tawbi, Matthias Pauschinger, Thomas F. Gajewski, Evan J. Lipson and Jason J. Luke

    Journal for ImmunoTherapy of Cancer 2016 4:50

    Published on: 16 August 2016

  6. Case report

    Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

    Immune checkpoint inhibitors have revolutionized cancer therapy since these drugs target inhibitory pathways on T cells, which result in durable anti-tumor immune responses and significant overall survival for...

    Mehmet Asim Bilen, Sumit K. Subudhi, Jianjun Gao, Nizar M. Tannir, Shi-Ming Tu and Padmanee Sharma

    Journal for ImmunoTherapy of Cancer 2016 4:36

    Published on: 21 June 2016

  7. Case report

    Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma

    Blockade of the immunological checkpoint programmed death 1 (PD-1) using monoclonal antibodies has shown robust anti-tumor activity across a broad range of solid and hematological malignancies including melano...

    Melina E. Marmarelis, Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri and Patrick A. Ott

    Journal for ImmunoTherapy of Cancer 2016 4:26

    Published on: 19 April 2016

  8. Case report

    Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid

    To date, patients with pre-existing autoimmune conditions have been excluded from immunotherapy trials out of concern for severe autoimmune exacerbations.

    Kristen M. Beck, Joanna Dong, Larisa J. Geskin, Vincent P. Beltrani, Richard G. Phelps, Richard D. Carvajal, Gary Schwartz, Yvonne M. Saenger and Robyn D. Gartrell

    Journal for ImmunoTherapy of Cancer 2016 4:20

    Published on: 19 April 2016

  9. Case report

    Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

    Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic mela...

    Viktor H. Koelzer, Sacha I. Rothschild, Deborah Zihler, Andreas Wicki, Berenika Willi, Niels Willi, Michèle Voegeli, Gieri Cathomas, Alfred Zippelius and Kirsten D. Mertz

    Journal for ImmunoTherapy of Cancer 2016 4:13

    Published on: 15 March 2016

  10. Case report

    Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab

    Immune related adverse events affecting various organ systems are a recognized potential consequence of immune checkpoint inhibition. However, autoimmune inner ear disease is one complication not previously as...

    Matthew Zibelman, Natasha Pollak and Anthony J Olszanski

    Journal for ImmunoTherapy of Cancer 2016 4:8

    Published on: 16 February 2016

  11. Case report

    Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations

    Mismatch repair deficiency (MMRD) is a common pathway of malignant transformation accounting for approximately 15–20 % of human carcinogensis. It has been postulated that MMRD increases tumor antigenicity and ...

    Michael P. Castro and Neal Goldstein

    Journal for ImmunoTherapy of Cancer 2015 3:58

    Published on: 15 December 2015

  12. Short report

    Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

    Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore...

    Jonathan D. Schoenfeld, Anand Mahadevan, Scott R. Floyd, Michael A. Dyer, Paul J. Catalano, Brian M. Alexander, David F. McDermott and Irving D. Kaplan

    Journal for ImmunoTherapy of Cancer 2015 3:50

    Published on: 15 December 2015

  13. Case Reports

    Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

    We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination ther...

    Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon and John L. Barstis

    Journal for ImmunoTherapy of Cancer 2015 3:41

    Published on: 15 September 2015

  14. Research article

    Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

    Osteosarcoma is one of the most common bone cancers in children. Most patients with metastatic osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have pr...

    Danielle M Lussier, John L Johnson, Pooja Hingorani and Joseph N Blattman

    Journal for ImmunoTherapy of Cancer 2015 3:21

    Published on: 19 May 2015

  15. Case Report

    Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

    Antibodies that stimulate the immune system by targeting inhibitory T cell receptors were successfully introduced into oncological practice and are capable to overcome tumor-induced immune evasion. In particul...

    Heinz Läubli, Cathrin Balmelli, Matthias Bossard, Otmar Pfister, Kathrin Glatz and Alfred Zippelius

    Journal for ImmunoTherapy of Cancer 2015 3:11

    Published on: 21 April 2015

  16. Case report

    Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

    Although animal studies have shown that the immunomodulator ipilimumab causes inflammation of the myocardium, clinically significant myocarditis has been observed only infrequently. We report a case of suspect...

    Benjamin P Geisler, Roy A Raad, Diana Esaian, Elad Sharon and David R Schwartz

    Journal for ImmunoTherapy of Cancer 2015 3:4

    Published on: 17 February 2015

  17. Case report

    Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma

    We report on a 36-year-old woman treated with the anti PD-1 antibody Pembrolizumab for metastatic cutaneous melanoma in the first line setting. She achieved a complete response and then relapsed with metastase...

    Joshua S Manusow, Leila Khoja, Nataly Pesin, Anthony M Joshua and Efrem D Mandelcorn

    Journal for ImmunoTherapy of Cancer 2014 2:41

    Published on: 16 December 2014

  18. Case report

    Ipilimumab in patients with melanoma and autoimmune disease

    Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To d...

    Chrisann Kyi, Richard D Carvajal, Jedd D Wolchok and Michael A Postow

    Journal for ImmunoTherapy of Cancer 2014 2:35

    Published on: 14 October 2014

  19. Case report

    Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

    Ipilimumab is a fully human, monoclonal antibody directed against Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) that has demonstrated a survival benefit and durable disease control in patients with advanced melano...

    Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke, John A Thompson, Keisuke Shirai, David Lawson, Heddy Bartell, Ragini Kudchadkar, Ngoc Thi Gunter, Janice M Mehnert and Evan J Lipson

    Journal for ImmunoTherapy of Cancer 2014 2:33

    Published on: 14 October 2014

Previous Page Page 2 of 3 Next Page
JITC logo

Advertisement